BOSTON, June 1, 2025 – Patients with colon cancer who consumed an anti-inflammatory diet during a phase 3 clinical trial showed longer overall survival post-treatment compared to those on a ...
The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...
The 3-year disease-free survival rate was 86.4% in the atezolizumab arm and 76.6% in the control arm. Adding atezolizumab to adjuvant treatment with mFOLFOX6 (folinic acid, fluorouracil, and ...
June 1, 2025 — The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab ...
Anlotinib versus bevacizumab added to standard first-line chemotherapy among patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer: A multicenter, prospective, randomised, phase ...
Staging means finding out how far colon cancer has spread in your body. Physicians group colon cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results